Actinium PharmaceuticalsATNM
ATNM
About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Employees: 37
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
1,417% more call options, than puts
Call options by funds: $91K | Put options by funds: $6K
93% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 14
1.09% less ownership
Funds ownership: 27.16% [Q3] → 26.07% (-1.09%) [Q4]
4% less funds holding
Funds holding: 72 [Q3] → 69 (-3) [Q4]
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
36% less capital invested
Capital invested by funds: $15.9M [Q3] → $10.2M (-$5.65M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
208%
upside
Avg. target
$4
208%
upside
High target
$4
208%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 61 / 413 met price target | 208%upside $4 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Based on 209 articles about ATNM published over the past 30 days
Neutral
PRNewsWire
1 hour ago
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM
NEW YORK , April 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM). Shareholders who purchased shares of ATNM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
GlobeNewsWire
1 hour ago
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical-stage biotechnology company advancing a distinctive portfolio of differentiated and highly targeted radiopharmaceuticals, today announced the signing of a supply agreement for Actinium-225 (Ac-225) to support the development of Alpha-9's radiopharmaceutical programs. Under the terms of the agreement, ITM will supply its therapeutic medical radioisotope, Ac-225, produced by ActineerTM Inc. (Actineer), the joint venture between ITM and Canadian Nuclear Laboratories. Actineer is advancing cutting-edge technologies to secure and expand its supply chain and produce industrial-scale quantities of Ac-225 at rapid speed to meet the growing global demand. Further contract details have not been disclosed.
Neutral
Accesswire
9 hours ago
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – ATNM
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144809&wire=1 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
9 hours ago
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK , April 23, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 26, 2025 lead plaintiff deadline. So what: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
9 hours ago
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144806&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
14 hours ago
Investors who Lost Money on Actinium Pharmaceuticals, Inc. (ATNM) Should Contact Levi & Korsinsky about Pending Class Action - ATNM
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144772&wire=1 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
17 hours ago
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Join Class Action Suit Seeking Recovery – Contact The Gross Law Firm
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Actinium Pharmaceuticals, Inc. (NYSE: ATNM).
Neutral
Accesswire
20 hours ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Shareholders
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144717&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
22 hours ago
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Actinium Pharmaceuticals, Inc. (ATNM) Shareholders
NEW YORK, NY / ACCESS Newswire / April 23, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=144637&wire=1 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
22 hours ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
NEW YORK CITY, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Charts implemented using Lightweight Charts™